Teva Pharmaceutical Industries Ltd. (NYSE:TEVA – Get Free Report) shares passed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $40.56 and traded as low as $38.51. Teva Pharmaceutical Industries shares last traded at $38.53, with a volume of 10,369,385 shares traded.
Key Headlines Impacting Teva Pharmaceutical Industries
These are some of the TEVA headlines that stood out recently:
- Positive Sentiment: A blended fair-value estimate for Teva rose to $50.51 from $48.94, with commentary citing its growth strategy and products including Austedo, Uzedy and Ajovy. The estimate is not a company forecast, but it adds to the constructive analyst tone. Read article
- Positive Sentiment: Zacks Research moved its rating from “strong sell” to “hold.” Barclays also raised its price target to $50 from $47 and maintained an “overweight” rating, signaling analysts see potential upside. Read rating information
- Negative Sentiment: A notice from investor-law firm SueWallSt says it is investigating potential claims related to the decline following Hughes’s departure. This is an investigation notice, not a finding of wrongdoing, but it adds a potential legal overhang. Read notice
Wall Street Analyst Weigh In
A number of analysts have recently weighed in on the company. TD Cowen raised their price target on Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Leerink Partners increased their price objective on shares of Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the stock an “outperform” rating in a report on Thursday, November 5th. Oppenheimer lifted their price objective on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, October 9th. UBS Group boosted their target price on shares of Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the company a “buy” rating in a research note on Friday, September 4th. Finally, Weiss Ratings raised Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, November 4th. Fourteen analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus target price of $48.64.
Check Out Our Latest Stock Analysis on TEVA
Teva Pharmaceutical Industries Stock Up 1.8%
The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 1.59. The firm has a market capitalization of $45.71 billion, a price-to-earnings ratio of 91.23, a PEG ratio of 3.69 and a beta of 0.97. The stock has a fifty day moving average of $40.60 and a 200-day moving average of $35.24.
Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last announced its earnings results on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, beating the consensus estimate of $0.72 by $0.14. The business had revenue of $4.39 billion during the quarter, compared to the consensus estimate of $4.23 billion. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. Teva Pharmaceutical Industries’s revenue was down 1.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.78 earnings per share. As a group, sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current year.
Insider Activity
In other news, insider Brian Savage sold 7,342 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, September 18th. The stock was sold at an average price of $38.85, for a total transaction of $285,236.70. Following the transaction, the insider owned 8,500 shares in the company, valued at approximately $330,225. The trade was a 46.35% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Roberto Mignone sold 367,600 shares of the company’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $39.06, for a total value of $14,358,456.00. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 715,945 shares of company stock worth $29,061,351. 0.54% of the stock is owned by corporate insiders.
Institutional Investors Weigh In On Teva Pharmaceutical Industries
A number of institutional investors have recently bought and sold shares of the business. Root Financial Partners LLC purchased a new position in Teva Pharmaceutical Industries during the third quarter valued at approximately $33,000. Western Wealth Management LLC purchased a new stake in Teva Pharmaceutical Industries in the 1st quarter worth approximately $43,000. Sunbelt Securities Inc. purchased a new stake in Teva Pharmaceutical Industries in the 1st quarter worth approximately $45,000. EverSource Wealth Advisors LLC boosted its stake in shares of Teva Pharmaceutical Industries by 64.0% during the 1st quarter. EverSource Wealth Advisors LLC now owns 1,658 shares of the company’s stock valued at $50,000 after buying an additional 647 shares during the period. Finally, CX Institutional acquired a new stake in shares of Teva Pharmaceutical Industries during the 2nd quarter valued at $54,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.
Recommended Stories
- Five stocks we like better than Teva Pharmaceutical Industries
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.
